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Abstract
Objective To evaluate the breadth, validity, and presence of biases of
the associations of vitamin D with diverse outcomes.
Design Umbrella review of the evidence across systematic reviews and
meta-analyses of observational studies of plasma 25-hydroxyvitamin D
or 1,25-dihydroxyvitamin D concentrations and randomised controlled
trials of vitamin D supplementation.
Data sources Medline, Embase, and screening of citations and
references.
Eligibility criteria Three types of studies were eligible for the umbrella
review: systematic reviews and meta-analyses that examined
observational associations between circulating vitamin D concentrations
and any clinical outcome; and meta-analyses of randomised controlled
trials assessing supplementation with vitamin D or active compounds
(both established and newer compounds of vitamin D).
Results 107 systematic literature reviews and 74 meta-analyses of
observational studies of plasma vitamin D concentrations and 87
meta-analyses of randomised controlled trials of vitamin D
supplementation were identified. The relation between vitamin D and
137 outcomes has been explored, covering a wide range of skeletal,
malignant, cardiovascular, autoimmune, infectious, metabolic, and other
diseases. Ten outcomes were examined by both meta-analyses of
observational studies and meta-analyses of randomised controlled trials,
but the direction of the effect and level of statistical significance was
concordant only for birth weight (maternal vitamin D status or
supplementation). On the basis of the available evidence, an association
between vitamin D concentrations and birth weight, dental caries in
children, maternal vitamin D concentrations at term, and parathyroid
hormone concentrations in patients with chronic kidney disease requiring
dialysis is probable, but further studies and better designed trials are
needed to draw firmer conclusions. In contrast to previous reports,
evidence does not support the argument that vitamin D only
supplementation increases bone mineral density or reduces the risk of
fractures or falls in older people.
Conclusions Despite a few hundred systematic reviews and
meta-analyses, highly convincing evidence of a clear role of vitamin D
does not exist for any outcome, but associations with a selection of
outcomes are probable.
Introduction
The associations between vitamin D concentrations and various
conditions and diseases have been assessed in a large and rapidly
expanding literature. In addition to observational studies,
numerous randomised trials have examined the effect of vitamin
D supplementation on a range of outcomes. Historically, vitamin
D had been linked to skeletal disease including calcium,
phosphorus, and bone metabolism,1 2 osteoporosis,3 fractures,4 5
muscle strength,6 and falls.7 In the 2000s, growing scientific
attention turned to non-skeletal chronic diseases as vitamin D
deficiency was linked to cancer,8 cardiovascular diseases,9 10
metabolic disorders,11 infectious diseases,12 and autoimmune
diseases,13-15 as well as mortality.16 If causal, these associations
might be of great importance for public health, as vitamin D
deficiency has been found to be highly prevalent in populations
residing at high latitudes or leading an indoors oriented
lifestyle.17However, the composite literature is often confusing
and has led to heated debates about the optimal concentrations
of vitamin D and related guidelines for supplementation.18-20
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To provide an overview of the breadth and validity of the
claimed associations of vitamin D with diverse outcomes, we
have done an umbrella review of the evidence across existing
systematic reviews and meta-analyses. We aimed to do a
comprehensive evaluation of systematic reviews and
meta-analyses of observational studies that examined
associations of vitamin D concentrations with a range of clinical
outcomes, as well as meta-analyses of randomised controlled
trials of vitamin D supplementation. We also compared the
findings of the observational studies with those from
meta-analyses of randomised controlled trials of vitamin D
supplementation, whenever these could be juxtaposed. We
sought to summarise the health outcomes that have been
associated with vitamin D concentrations, evaluate whether
evidence exists of biases in this literature, identify health
outcomes without evidence of biases, and examine the
consistency of inferences from the meta-analyses of
observational studies and of randomised controlled trials.
Methods
Structure of umbrella review
An umbrella review systematically collects and evaluates
information frommultiple systematic reviews andmeta-analyses
on all clinical outcomes for which these have been performed.21
Here, for evidence on observational associations between
vitamin D concentrations and any health outcome, we sought
to collect information from systematic reviews regardless of
whether they also included quantitative syntheses
(meta-analyses). Given the very large heterogeneity that may
be encountered in observational studies, often meta-analysis
may not be done in systematic reviews of observational studies,
whereas this problem occurs much less frequently in systematic
reviews of randomised controlled trials, for whichmeta-analysis
is the norm, especially when interventions are drugs or
vitamins.22 Where available, we also evaluated in more depth
the quantitative results of the meta-analyses of observational
associations and potential hints of bias in these
meta-analyses.23-25 For evidence on randomised controlled trials
of vitamin D supplementation, we considered only formal
quantitative meta-analyses. We compared results from
meta-analyses of observational studies and randomised
controlled trials, whenever data were available for the same
outcome.
Search strategy
Two reviewers (IT, ET) searched Medline and Embase in
duplicate, using the search algorithm in supplementary table A,
from inception to 11 October 2013 (last update) and limited the
search to humans and English language, as the overwhelming
majority of review studies are published in English language,
peer reviewed journals. Any discrepancies were resolved with
discussion. We firstly perused the title and abstract of each of
these citations and then retrieved potentially eligible articles for
perusal in full text.
Eligibility criteria and appraisal of included
studies
Three types of studies were eligible for the umbrella review:
observational associations between circulating vitamin D
concentrations and any clinical outcome examined in systematic
reviews, meta-analyses, or both; and meta-analyses of
randomised controlled trials assessing supplementation of
vitamin D or active compounds (both established and newer
compounds of vitamin D). We excluded studies that examined
genetic polymorphisms related to vitamin D metabolism (for
example, vitamin D receptor); systematic reviews and
meta-analyses of observational studies assessing dietary or
supplementary vitamin D intake or ultraviolet B exposure;
studies that had vitamin D status as the outcome; studies that
investigated the prevalence of vitamin D deficiency in certain
disease populations; andmeta-analyses of randomised controlled
trials in which the treatment arm combined vitamin D with
calcium or other vitamins or compounds versus placebo. When
the treatment arm and control arm included the same additional
compound (for example vitamin D and calcium versus calcium),
we included the meta-analysis in the review. We included
meta-analyses regardless of the baseline characteristics (clinical
setting or age) of the examined populations. If an article
presented separate meta-analyses on more than one eligible
outcome or type of clinical setting, we assessed those separately.
Appraisal of individual component studies was beyond the scope
of this umbrella review. This was the aim of the original
systematic reviews and meta-analyses, which should include
an appraisal of studies’ quality. In respect to the selected
systematic reviews and meta-analyses, we used methods that
captured essential features of the quality of the evidence, and
these are described in detail in the data analysis section.
Data extraction
Three investigators (ET, IT, LZ) extracted data independently.
From each eligible systematic review or meta-analysis, we
abstracted the PubMed ID, first author, journal, year of
publication, vitamin D biomarker, population, and outcome
examined. From each systematic review of observational studies,
we recorded a statement summarising the authors’ main
interpretations of their findings. From each meta-analysis of
observational studies or randomised controlled trials, we further
abstracted data on the studies included in the analysis: the study
specific relative risk estimates (risk ratio, odds ratio, hazard
ratio, or incident risk ratio, as reported by the authors of the
meta-analysis), along with the corresponding confidence
intervals and the number of cases and controls for each study.
We categorised outcomes into the following categories:
autoimmune diseases, cancer outcomes, cardiovascular
outcomes, cognitive disorders, infectious diseases, metabolic
disorders, neonatal/infant/child related outcomes, pregnancy
related outcomes, skeletal outcomes (including falls), and
“other” outcomes (supplementary table B).
Data analysis
We carried out descriptive analysis for systematic reviews. We
categorised the conclusions of each systematic review for the
association of vitamin D and the outcome of interest in one of
the following four categories: definite association, suggestive
(possible) association, no association, or inconclusive
(insufficient) evidence. Whenever more than one systematic
review had been performed on the same outcome, we examined
whether the main reported conclusions were concordant. We
retained the most recent systematic review for further analyses.
When we identified more than one meta-analysis of
observational studies examining the association between a given
vitamin D biomarker and outcome pair in the same clinical
setting, we examined the conclusions for concordance regarding
the direction, level of statistical significance (at P≤0.05), and
magnitude (overlapping confidence interval) of the association.
Then, we again retained only the most recent meta-analysis with
eligible data for further statistical analysis. We estimated the
summary effect size and its confidence interval by using random
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effects models and calculated the I2 and its confidence interval
metric for heterogeneity for each eligible meta-analysis that
reported the effect sizes, number of cases, and total number of
participants of the component studies.26 27We used the regression
asymmetry test to test for small study effects.28 We also applied
the excess significance test, which evaluates whether the
observed number of studies with statistically significant results
(“positive” studies) differs from the expected number of positive
studies, by using a χ2 test.29-31 The expected number of positive
studies for each meta-analysis is calculated by the sum of the
statistical power estimates for each component study. We
estimated the power of each study for an effect equal to the
effect of the largest study (study with the smallest variance), as
previously described.32 We used appropriate equations to
estimate the power, on the basis of whether the largest study
reported a hazard ratio or an odds ratio.33 34 If the type of the
metric was a standardisedmean difference, we transformed this
to an odds ratio before using it in the analysis.
Eight meta-analyses presented in five papers were not included
in the excess significance bias analysis either because individual
study data was unavailable35 36 or because it reported the
logarithm of geometric mean ratio,37 the weighted mean
difference,36 or the Fisher’s z score.38 Both the small study and
excess significance tests were considered significant at P<0.10,
as previously proposed.23
We specifically identified outcomes for which meta-analyses
of observational studies showed nominally significant
associations (at P≤0.05), did not have large between study
heterogeneity, were based on evidence from more than 500
cases (or more than 5000 total participants if the type of metric
was continuous), and showed no evidence of small study effects
or excess significance. We also noted how many would satisfy
the same criteria but with P≤0.001, which has been considered
to be a more appropriate threshold of statistical significance to
reduce false positives.39-41
Whenwe identified more than one meta-analysis of randomised
controlled trials examining the relation between vitamin D
supplementation and outcome pair in the same clinical setting,
we examined the conclusions for concordance regarding the
direction, level of statistical significance (at P≤0.05), and
magnitude (overlapping confidence interval) of the association.
When meta-analyses for the same outcome existed both for
association studies of vitamin D concentrations and for
randomised controlled trials of vitamin D supplementation, we
compared their results in terms of whether a nominally
statistically significant effect had been described (P≤0.05) and
whether the effect estimate was in the same direction. We did
not compare the magnitude of the effect sizes between
circulating vitamin D concentrations and vitamin D
supplementation, as these are difficult to translate to the same
vitamin D concentration/treatment contrasts. Whenever no
meta-analysis of observational studies existed for an outcome
examined by a meta-analysis of randomised controlled trials,
we compared the main results with the results of a systematic
review of observational studies, if available. Finally, we applied
a set of criteria to conclude whether the evidence for a given
outcome was definite, probable, suggestive, not conclusive, or
unlikely (see box).
We used Stata version 12.1 for statistical analyses. P values
were two tailed.
Results
Overall, 1256 articles searched yielded 107 systematic reviews
without meta-analyses (presented in 24 papers)36 42-64 and 74
meta-analyses (47 papers)11 35-38 52 65-105 of observational studies
that investigated associations with circulating vitamin D
concentrations. In addition, we identified and included 87
meta-analyses (32 papers)5 7 37 52 61 70 106-131 of randomised
controlled trials of vitamin D supplementation (fig 1⇓;
supplementary tables C-E). Across all three study types, results
on 137 unique outcomes were reported (fig 2⇓; supplementary
table B).
Vitamin D concentrations and health
outcomes: systematic reviews of
observational studies
The median number of observational studies included in the
systematic reviews was four (range 1-28) (supplementary table
C). Among the 107 identified systematic reviews, 76 unique
ones were presented in 21 papers (supplementary table
B),36 43-49 52-64 whereas more than one systematic review existed
for 24 outcomes (in 15 of which the authors reached the same
qualitative conclusion; supplementary table C).
For only six (8%) of the 76 unique outcomes, the systematic
reviews concluded that a definite association existed
(supplementary tables B and F). These were rheumatoid arthritis
activity, colorectal cancer, hypertension in children, bacterial
vaginosis in pregnant women, falls in older people, and rickets
in children; for all these outcomes, higher concentrations of
vitamin D were associated with lower risk. Conversely, for 10
(13%) outcomes, the authors concluded that no association
existed between the examined outcome and vitamin D status.
For 60 of the 76 unique outcomes, the systematic reviews did
not reach a firm, unequivocal conclusion: for 43 (57%) authors
reported that the reviewed data were inconclusive or insufficient
to draw any firm conclusions, and 17 (22%) found that an
inverse association was possible or suggestive. No systematic
reviews concluded that a definite or suggestive association
existed for increased risk with higher concentrations of vitamin
D.
Vitamin D concentrations and health
outcomes: meta-analyses of observational
studies
We identified 74 meta-analyses of observational studies
(supplementary table D). Among these, 48 uniquemeta-analyses
were presented in 28 papers (fig 1⇓; supplementary table
G).35-38 66 68 71 74 76 78 79 82-84 86 88 89 91 95 96 98-105 Forty three
meta-analyses examined the link between vitamin D and
outcome by using 25-hydroxyvitamin D and five by using
1,25-dihydroxyvitamin D. All meta-analyses reported estimates
adjusted for a wide variety of other covariates. Meta-analyses
examined a very wide range of outcomes including cancers
(n=20), cardiovascular diseases (n=8), cognitive disorders (n=4),
metabolic disorders (n=4), neonatal/infant/child related outcomes
(n=4), skeletal diseases (n=3), pregnancy related outcomes
(n=2), infectious disease (n=1), or other outcomes (n=2)
(supplementary table G). Themedian number of studies included
was seven (range 2-37), the median number of participants was
5905 (39-82 982), and the median number of events was 1289
(18-15 447). Overall, 30 (63%) of the 48 meta-analyses of
observational studies reported a nominally statistically
significant summary result (tables 1⇓ and 2⇓). Figure 3⇓ shows
a forest plot with the summary effects of all the non-overlapping
meta-analyses of observational studies (for binary outcomes).
We found more than one published meta-analysis for 11
outcomes: Alzheimer’s disease (n=2 meta-analyses), breast
cancer (n=6), colorectal adenoma (n=3), colorectal cancer (n=7),
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Criteria for evidence categories
Convincing—Evidence existed from both observational studies and randomised controlled trials (RCTs), and association/effect was of
the same direction, statistically significant at P≤0.001, and free from bias
Probable—Evidence existed from both observational studies and RCTs, and association/effect was of the same direction and statistically
significant at P≤0.001, but excess significance could not be tested; or evidence existed from RCTs and effect was statistically significant
at P≤0.001 and with no contrary results from observational data (that is, systematic reviews, if any exist, are also definitive or suggestive
and meta-analyses of observational studies, if any exist, are in the same direction)
Suggestive—Evidence fromRCTs with an effect at 0.001≤ P≤0.05 and with no contrary results from observational data (same as above);
or evidence from meta-analyses of observational studies showing an association at P≤0.001, with no contrary results from randomised
data (that is, meta-analysis of RCTs, if present, have effects in the same direction) and, if it could be tested, no evidence of small study
effects (P≥0.10), not very large heterogeneity (I2≤75%), no evidence for excess significance, based on cumulative evidence of more
than 500 disease events (or more than 5000 total participants if type of metric was continuous)
No conclusion—Not enough evidence from observational studies or RCTs to draw conclusion
Substantial effect unlikely—Evidence from observational studies or RCTs enough to conclude that a substantial effect is unlikely based
on the magnitude and the significance level
cardiovascular diseases (n=3), gestational diabetes (n=2),
hypertension (n=3), prostate cancer (n=4), stroke (n=2), type 2
diabetes (n=3), and prevalence of type 2 diabetes (n=2). For all
the outcomes, agreement existed between the meta-analyses on
the direction, magnitude, and statistical significance of the
association (supplementary table H).
Summary effects, heterogeneity, and bias
tests for meta-analyses of observational
associations
Of the 48 non-overlapping meta-analyses of observational
studies, the largest study had statistically significant results in
21 (44%) meta-analyses (supplementary figure A). The largest
study’s result was more conservative than the summary result
in 20 (42%) meta-analyses. Fifteen (31%) meta-analyses had
large heterogeneity (I2>50%), and seven (15%) had very large
heterogeneity (I2>75%). Evidence for significant small study
effects was noted in three meta-analyses (breast cancer, all cause
mortality, and cardiovascular disease mortality) (tables 1⇓ and
2⇓). Evidence for statistically significant excess significance
bias was seen for three outcomes (sporadic colorectal adenoma
recurrence, Alzheimer’s disease, and fractures; supplementary
table I).
Significant observational associationswithout
hints of bias
Of the 48 meta-analyses, 18 (38%) had nominally statistically
significant summary associations according to random effects
calculations and had no evidence of small study effects (P≥0.10),
not very large heterogeneity (I2≤75%), and no evidence for
excess significance (tables 1⇓ and 2⇓). Overall, 12 of these 18
associations were based on cumulative evidence of more than
500 disease events (or more than 5000 total participants if the
type of metric was continuous) and also had P≤0.001 for the
association. These included vitamin D associations with one
cancer (colorectal cancer), five cardiovascular (cardiovascular
disease, prevalence of cardiovascular disease, hypertension,
ischaemic stroke, and stroke), two cognitive (cognition and
depression (cohort studies)), two metabolic (prevalence of
metabolic syndrome and type 2 diabetes), one
neonatal/infant/child related (small for gestational age), and one
pregnancy related outcome (gestational diabetes). Across these
12 associations, the relative risk of the highest versus the lowest
category had a median of 0.63 (interquartile range 0.52-0.67).
Meta-analyses of randomised controlled trials
of vitamin D supplementation
We identified 87 meta-analyses of randomised controlled trials
of vitamin D supplementation (supplementary table E). Among
these, 57 non-overlapping meta-analyses were presented in 19
papers,5 61 107 108 110-112 114 115 118-121 123 125 127 128 130 131 including 21
(37%) in skeletal diseases, seven (12%) in metabolic disorders,
four (7%) in neonatal/infant/child related outcomes, three (5%)
in cardiovascular diseases, three (5%) in pregnancy related
outcomes, and 18 (32%) in other outcomes. Themedian number
of studies included was four (range 2-38), and the median
number of participants was 446 (38-25 016) (tables 3⇓ and 4⇓).
Overall, 13 (23%) of the 57 meta-analyses of randomised
controlled trials reported a nominally statistically significant
summary result, and these were related to the following
outcomes: total cholesterol concentrations, birth weight, head
circumference at birth, maternal vitamin D concentrations at
term, balance sway, femoral neck bone mineral density, muscle
strength, non-vertebral fractures, rate of falls, dental caries in
children, parathyroid hormone concentrations in patients with
chronic kidney disease (requiring or not requiring dialysis), and
risk of hypercalcaemia in patients with chronic kidney disease
not requiring dialysis (tables 3⇓ and 4⇓). Figure 4⇓ shows a
forest plot with the summary effects of all the non-overlapping
meta-analyses of randomised controlled trials (for binary
outcomes).
We foundmore than onemeta-analysis of randomised controlled
trials for 10 outcomes: cardiovascular disease (n=2
meta-analyses), diastolic blood pressure (n=3), systolic blood
pressure (n=3), birth weight (n=3), falls (n=11), fractures (n=5),
hip fractures (n=4), non-vertebral fractures (n=2), rate of falls
(n=3), and mortality (n=5). For half of the outcomes, agreement
existed between the meta-analyses on the direction, magnitude,
and statistical significance of the effect. Only one of the
overlapping meta-analyses reported a statistically significant
effect for diastolic blood pressure, birth weight, and
non-vertebral fractures. Eleven meta-analyses examined risk of
falling, and differences existed in both the magnitude and the
statistical significance of the effect but not in the direction of
the effect. Finally, three meta-analyses examined rate of falls,
and differences existed in the direction, magnitude, and
statistical significance of the effect (supplementary table J).
Comparison of findings from observational
studies and clinical trials
One hundred and twenty three (90%) outcomes were examined
only by syntheses of observational evidence (n=84) or only by
meta-analyses of randomised evidence (n=39), so we could not
compare observational and randomised evidence.
Ten (7%) outcomes were examined by both meta-analyses of
observational studies and meta-analyses of randomised
controlled trials: cardiovascular disease, hypertension, birth
weight, birth length, head circumference at birth, small for
gestational age birth, mortality in patients with chronic kidney
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disease, all cause mortality, fractures, and hip fractures (table
5⇓). The direction of the association/effect and level of statistical
significance was concordant only for birth weight, but this
outcome could not be tested for hints of bias in the meta-analysis
of observational studies (owing to lack of the individual data).
The direction of the association/effect but not the level of
statistical significance was concordant in six outcomes
(cardiovascular disease, hypertension, birth length, head
circumference small for gestational age births, and all cause
mortality), but only two of them (cardiovascular disease and
hypertension) could be tested and were found to be free from
hint of bias and of low heterogeneity in the meta-analyses of
observational studies. For mortality in chronic kidney disease
patients, fractures in older populations, and hip fractures, both
the direction and the level of significance of the
association/effect were not concordant.
Finally, four (3%) outcomes were examined by meta-analyses
of randomised controlled trials and systematic reviews of
observational studies without a formal meta-analysis
(supplementary table B). These included falls, for which
systematic reviews concluded that a definite association existed
whereas meta-analyses of randomised controlled trials reported
a non-statistically significant effect, and length of gestation and
bone mineral density in adults and in children, for which the
systematic reviews concluded that a suggestive association
existed whereas meta-analyses of randomised controlled trials
reported a non-statistically significant effect.
Discussion
Our umbrella review identified 107 systematic literature reviews
and 74meta-analyses of observational studies of plasma vitamin
D concentrations and 87meta-analyses of randomised controlled
trials of vitamin D supplementation. The role of vitamin D has
been explored in relation to an impressive number of outcomes
(137 in total), covering a wide range of diseases, including
among others skeletal, malignant, cardiovascular, autoimmune,
infectious, and metabolic diseases. We identified a gap in the
literature concerning autoimmune disease outcomes, as we found
no formal meta-analyses of either observational studies or
randomised controlled trials and these were examined only by
systematic reviews. Furthermore, cancer, cognitive, and
infectious disease outcomes were examined only in
observational studies of plasma vitamin D concentrations (either
systematic reviews or formal meta-analyses), and we found no
meta-analyses of randomised controlled trials of vitamin D
supplementation. Comparisons of syntheses of observational
versus randomised evidence were possible for only 14 of the
137 outcomes. Largely, this unevenness in observational versus
randomised evidence may reflect the low frequency of many of
these outcomes, which would be difficult to study conclusively
with randomised trials.
Most of the associations that give signals of nominal significance
for diverse outcomes are subject to the caveats that generally
accompany evidence from observational studies: many of them
may be false positives, and very few, if any, may translate to
effective interventions when tested in randomised trials. Even
meta-analyses of randomised trials may not be conclusive,
especially when based on limited sample size and weak levels
of statistical significance. On the basis of the results of this
umbrella review (table 6⇓), highly convincing evidence of a
clear role of vitamin D with highly significant results in both
randomised and observational evidence does not exist for any
outcome. Vitamin D supplementation is probably linked to a
decrease in dental caries in children and in parathyroid hormone
concentrations in patients with chronic kidney disease requiring
dialysis and to an increase in maternal vitamin D concentrations
at term and in birth weight. Suggestive evidence exists for a
correlation between high vitamin D concentrations and low risk
of colorectal cancer, non-vertebral fractures, cardiovascular
disease, prevalence of cardiovascular disease, hypertension,
ischaemic stroke, stroke, cognition, depression, high body mass
index, prevalence of metabolic syndrome, type 2 diabetes, head
circumference at birth, small for gestational age birth, and
gestational diabetes mellitus; reduced levels of balance sway,
alkaline phosphatase concentrations in chronic kidney disease
patients requiring dialysis, and parathyroid hormone
concentrations in chronic kidney disease patients not requiring
dialysis; and increased levels of low density lipoprotein, bone
mineral density in femoral neck, and muscle strength. On the
other hand, suggestive evidence exists that high vitamin D
concentrations are linked to an increased rate of falls and risk
of hypercalcaemia in chronic kidney disease patients not
requiring dialysis.
Most (30/48) of the meta-analyses of observational studies
reported a nominally statistically significant result. However,
meta-analyses of randomised controlled trials reported a
nominally statistically significant summary result for only 13
of the 57 outcomes, and the confidence intervals of the estimates
were generally wider than the confidence intervals of the
meta-analyses of observational studies. This may reflect lower
power in meta-analyses of randomised controlled trials (due to
fewer included studies and participants) and a different range
of examined outcomes, or it may in part be due to the more
conservative results in randomised controlled trials than in
observational studies. The highly promising results identified
from most of the meta-analyses of observational studies were
either not tested or not replicated inmeta-analyses of randomised
controlled trials. In most cases, this was not only a matter of
statistical significance but in addition the meta-analysis effect
estimates were close to null for the randomised controlled trials.
Genuine differences between these two designs might be due
to confounding or biases that operate in observational studies.
Alternatively, difficulties in relation to randomised controlled
trials of vitamin D supplementation may affect reliability of
findings. “Typical” difficulties concern disentangling the effects
of multiple compounds when administered simultaneously and
assuring an appropriate follow-up period: although this would
have been assured for primary outcomes, the follow-up time
may be inadequate to allow differences in disease occurrence
to become apparent for secondary outcomes. Similarly, an
inappropriately low dose or short duration of vitamin D
supplementation in the randomised controlled trials might be
inadequate to raise the body’s vitamin D concentrations enough
to show a difference between the arms of a trial. Differences in
vitamin D concentrations achieved following supplementation
can be much smaller than naturally occurring variation in the
general population.132 Moreover, large differences in baseline
plasma concentrations of 25-hydroxyvitamin D in different
populations could interfere with the effect of the
supplementation. Finally, contamination with private use of
vitamin D might also further dilute any definite associations.133
Strengths and weaknesses of study and in
relation to other studies
This umbrella review provides a comprehensive summary of
the published literature in relation to the role of vitamin D in
human diseases and health related traits. Beyond summarising
the findings for a wide range of outcomes, we explored the
extent of bias and heterogeneity in the observational vitamin D
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literature. As in all literature reviews, the quality is directly
related to the quality of the included studies. Furthermore, some
health related outcomes were poorly covered, and we have
flagged this gap. Exploring the relation between vitamin D
supplementation dose and effect size reported in randomised
controlled trials was beyond the scope of this review. Similarly,
we could not evaluate the effect of the different choices of
comparison groups (for example, thirds, quarters, fifths) or of
varying vitamin D distributions and median differences of the
component observational studies.
We decided to exclude observational meta-analyses of vitamin
D supplementation and include only meta-analyses of
randomised controlled trials in relation to vitamin D
supplementation. Meta-analyses of randomised controlled trials
are subject to considerably less bias than are those of
observational studies and are therefore selected as the standard
against which observational meta-analyses of vitamin D
concentrations are compared. Meta-analyses of observational
studies of supplement intake are unlikely to be more reliable
than the meta-analyses of observational studies of associations
with vitamin D concentrations, so one could not really use them
as a gold standard for assessing how the bias, size, or
heterogeneity mapping performs.
We did not identify prominent bias in the observational plasma
vitamin D literature, with respect to either the excess
significance test (which evaluates whether the results of single
studies are over-optimistic compared with the results of the
largest study) or the small study effects test (which evaluates
whether small studies are consistently more positive or negative
than larger studies). This differs from findings of other empirical
evaluations of biomarker studies.23-25 This is because large
studies in our review had relatively similar results to other
studies and to the summary meta-analysis effect. This might
mean that the same confounding or other biases affected all
studies regardless of sample size. Other types of confounding
or biases, such as reverse causality, might operate in this field,
and these tests are not designed to probe this.
As we were preparing our review for submission, a relevant
overview of observational studies and randomised controlled
trials of vitamin D status or supplementation and ill health was
published online.132 Eligible papers included prospective cohort
studies and randomised controlled trials on chronic diseases
(excluding skeletal diseases) in adults and were identified
through a search in PubMed and Embase from inception to 31
December 2012. The authors identified 82 prospective cohort
studies, 84 randomised controlled trials, 20 meta-analyses of
208 prospective studies, and eight meta-analyses of 88
randomised controlled trials. Similarly to our findings, this
overview identified a discrepancy between findings of
observational studies and of randomised controlled trials, with
most supplementation trials not showing an effect of vitamin
D on disease occurrence, and the authors concluded that low
vitamin D status is more likely to be a marker of ill health than
a cause of disease. The results of this overview were similar to
ours, but our review is more comprehensive in terms of the
number and range of outcomes covered and different regarding
the included studies (we included systematic reviews and
meta-analyses rather than original studies), the underlying
population (we did not restrict our analysis to adults or particular
clinical settings), and the statistical analyses performed
(including bias tests).
Possible explanations and implications for
clinicians and policy makers
No universal consensus exists on the optimal vitamin D intake
or the optimal plasma concentrations of 25-hydroxyvitamin D.
The Institute of Medicine issued a report in 2011 stating that
25-hydroxyvitamin D concentrations of 50 nmol/L are adequate
and suggested that these concentrations can be achieved by 600
IU of vitamin D per day.20 Furthermore, vitamin D
supplementation has been long thought to protect against
osteoporosis and consequently to reduce the risk and number
of fractures, so large numbers of older adults use vitamin D
supplements.134 That nearly half of the meta-analyses of
randomised controlled trials were related to skeletal diseases is
not surprising. Several randomised controlled trials have
identified a protective effect of vitamin D supplementation (with
or without co-administration of calcium) against fractures,135 136
but trials that examined vitamin D only supplementation failed
to replicate these findings.107 Similarly, a very recent
meta-analysis of randomised controlled trials on bone mineral
density failed to show a definite association and concluded that
widespread use of vitamin D supplementation for prevention
of osteoporosis is not supported by the evidence,131 a fact that
is also verified by the findings of our review. Vitamin D might
not be as essential as previously thought in maintaining bone
mineral density. Similar are our findings for falls, with the
results of two recent Cochrane reviews failing to find a
protective effect of vitamin D only supplementation on the risk
or rate of falling in older adults (both in care facilities or
hospitals and in the community).111 115
The lack of convincing associations and the relative dearth of
probable associations (table 6⇓) suggest that evidence for
benefits that may be reaped from population-wide vitamin D
supplementation is weak. Probable associations, where highly
significant effects appear in randomised trials, hold the most
promise for clinical translation, but they pertain to specific
populations (children, pregnant women, patients with chronic
kidney disease), and even in these cases the evidence is not
sufficient tomake universal recommendations about daily intake.
Optimal vitamin D intake/concentration may not be the same
for all outcomes.137 In addition, the absorption/metabolism of
vitamin D differs among individuals; in practice, this means
that the same supplementation dose is not going to have a stable
effect on plasma vitamin D concentration, introducing yet
another source of variability. Moreover, individual
characteristics (such as bodymass index or disease) will further
modify final concentrations in circulation. In this regard, current
recommendations on daily supplementation of vitamin D are
largely expert driven, rather than evidence based,20 and this may
be the reason why they have generated so much debate. Some
recommendations that focus on specific outcomes such as
prevention of falls and fractures and in which even higher doses
of vitamin D are recommended (for example, the American
Endocrine Society,138 Osteoporosis Canada139) seem actually to
be contradicted by the evidence, which shows no consistent
beneficial effects in randomised trials. Our overview of the
evidence on vitamin D suggests that strong recommendations
cannot be made regarding its supplementation.
Conclusions, unanswered questions, and
future research
In conclusion, although vitamin D has been extensively studied
in relation to a range of outcomes and some indications exist
that low plasma vitamin D concentrations might be linked to
several diseases, firm universal conclusions about its benefits
cannot be drawn. Observational studies have identified links
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with several diseases, but these have either not been evaluated
or not been replicated in randomised controlled trials.
Randomised controlled trials for autoimmune and cancer related
outcomes are clearly lacking. In addition, earlier evidence from
randomised controlled trials that vitamin D supplementation
(with or without calcium) increases bone mineral density and
reduces the risk of fractures in older people is not seen in clinical
trials that examine vitamin D only supplementation. On the
basis of the results of this review, an association between
vitamin D concentrations and birth weight, dental caries in
children, maternal vitamin D concentrations at term, and
parathyroid hormone concentrations in patients with chronic
kidney disease requiring dialysis is probable, but further studies
and better designed trials are needed to draw firmer conclusions.
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What is already known on this topic
The role of vitamin D has been explored both in a large number of observational studies and randomised controlled trials and in relation
to a multitude of health outcomes
The composite literature is often confusing and has led to heated debates about the role of vitamin D, the optimal concentrations, and
related guidelines for supplementation
Recent reports have highlighted the lack of concordance between observational studies and randomised controlled trials, concluding
that vitamin D is more likely to be a correlate marker of overall health and not causally involved in disease
What this study adds
This umbrella review collectively presents the evidence from systematic reviews and meta-analyses of observational studies and
randomised controlled trials in relation to 137 different outcomes covering a wide range of diseases
An association between vitamin D concentrations and birth weight, dental caries in children, maternal vitamin D concentrations at term,
and parathyroid hormone concentrations in chronic kidney disease patients requiring dialysis is probable
In contrast to previous reports, the findings cast doubt on the effectiveness of vitamin D only supplementation for prevention of osteoporosis
or falls
This review highlights the absence of meta-analyses in relation to autoimmune disease and the absence of meta-analyses of randomised
clinical trials of vitamin D supplementation in respect of cancer, cognitive, and infectious disease outcomes
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Tables
Table 1| Characteristics andmain findings of meta-analyses of observational studies reporting unique cancer and cardiovascular outcomes
(direction of comparison is high versus low)
Egger test
P valueI2 (95% CI)P value
Relative risk (95%
CI)*Total No
No of
events
No of
studies
Meta-analysis
metricBiomarkerOutcome
in each
MA
Cancer outcomes
0.9733 (0 to 73)0.810.98 (0.84 to 1.15)45248716OR25OHDAggressive prostate
cancer
NA0 (NA)0.210.75 (0.48 to 1.17)14886962OR1,25(OH)2DAggressive prostate
cancer
0.0688 (83 to 91)1.0×10−50.55 (0.42 to 0.71)26 31711 77121OR25OHDBreast cancer
0.8647 (0 to 84)0.960.99 (0.68 to 1.44)362718023OR1,25(OH)2DBreast cancer
0.920 (0 to 54)0.330.99 (0.97 to 1.01)876639299RR25OHDBreast cancer:
postmenopausal
0.7637 (0 to 74)0.671.01 (0.97 to 1.06)289016136RR25OHDBreast cancer:
premenopausal
0.1550 (0 to 74)0.130.78 (0.56 to 1.07)4578182210OR25OHDColon cancer
NANA0.570.88 (0.57 to 1.35)No infoNo info4OR1,25(OH)2DColon cancer
0.400 (0 to 53)0.00020.70 (0.58 to 0.84)6712276410RR25OHDColorectal cancer
NANA0.971.01 (0.59 to 1.73)No infoNo info4OR1,25(OH)2DColorectal cancer
0.370 (0 to 61)0.971.01 (0.65 to 1.58)14807406OR25OHDKidney cancer
0.560 (0 to 68)0.590.81 (0.39 to 1.70)39184OR25OHDNon-Hodgkin’s
lymphoma (females)
0.7213 (0 to 66)0.180.65 (0.35 to 1.23)65256OR25OHDNon-Hodgkin’s
lymphoma (males)
0.310 (0 to 53)0.180.83 (0.63 to 1.09)248988410OR25OHDOvarian cancer
0.9017 (0 to 67)0.042.13 (1.02 to 4.47)21138666OR25OHDPancreatic cancer
0.4340 (0 to 74)0.890.99 (0.87 to 1.14)364013617OR1,25(OH)2DProstate cancer
0.790 (0 to 47)0.151.04 (0.98 to 1.09)28 988435314OR25OHDProstate cancer
0.1051 (0 to 75)0.010.50 (0.29 to 0.88)20508689OR25OHDRectal cancer
0.3466 (13 to 82)0.020.82 (0.69 to 0.97)626829239OR25OHDSporadic colorectal
adenoma
0.3555 (0 to 86)0.530.87 (0.57 to 1.33)13665863OR25OHDSporadic colorectal
adenoma recurrence
Cardiovascular outcomes
0.5174 (54 to 83)9.7×10−50.67 (0.55 to 0.82)64 722760016OR25OHDCardiovascular disease
(prevalent)
0.9861 (28 to 75)1.6×10−70.66 (0.57 to 0.77)66 488612319RR25OHDCardiovascular disease
0.0981 (40 to 90)0.0060.55 (0.36 to 0.85)24 38720075RR25OHDCardiovascular disease
mortality
0.9244 (0 to 75)0.00040.70 (0.58 to 0.86)48 63349657RR25OHDHypertension
0.2780 (69 to 86)4.1×10−90.72 (0.65 to 0.81)82 982837619HR25OHDIschaemic heart
disease
0.6371 (0 to 86)2.1×10−50.66 (0.55 to 0.80)26 59618004HR25OHDIschaemic stroke (HR)
0.970 (0 to 64)2.3×10−140.52 (0.44 to 0.61)31 8588445OR25OHDIschaemic stroke (OR)
0.940 (0 to 58)1.8×10−60.61 (0.50 to 0.75)39 09512147RR25OHDStroke
HR=hazard ratio; MA=meta-analysis; NA=not applicable; OR=odds ratio; RR=relative risk.
P values were estimated using formulas presented in Altman and Bland 2011.140
*Effect estimate and 95% CI estimated on basis of random effects model. Reported effect estimates and 95% CI are presented for colon cancer (1,25(OH)2D)
and colorectal cancer (1,25(OH)2D).
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Table 2| Characteristics and main findings of meta-analyses of observational studies reporting unique cognitive, infectious, metabolic,
neonatal/infant/child related, pregnancy related, skeletal, and other outcomes (direction of comparison is high versus low)
Egger test
P valueI2 (95% CI)P value
Relative risk (95%
CI)*Total No
No of
events
No of
studies
Units
Meta-analysis
metricBiomarkerOutcome
in each
MA
Cognitive disorders
0.3298 (97 to 98)0.020.08 (0.01 to 0.63)10053577NASMD (to OR)25OHDAlzheimer’s disease
0.1656 (0 to 79)2.2×10−130.42 (0.34 to 0.53)900412177NAOR25OHDCognition
0.2253 (0 to 76)0.050.77 (0.59 to 1.00)19 80720519NAOR25OHDDepression
(case-control
studies)
0.4928 (0 to 80)0.0010.44 (0.27 to 0.72)88156173NAHR25OHDDepression (cohort
studies)
Infectious diseases
0.7941 (0 to 74)2.0×10−70.29 (0.19 to 0.46)5343087NASMD (to OR)25OHDTuberculosis
Metabolic disorders
NANA8.9×10−13−0.15 (−0.19 to
−0.11)
16 525NA37NAZ score25OHDBody mass index
0.5938 (0 to 71)1.4×10−70.49 (0.38 to 0.64)31 41628218NAOR25OHDMetabolic syndrome
(prevalent)
0.581 (0 to 46)5.0×10−170.63 (0.56 to 0.69)72 204487716NAOR25OHDType 2 diabetes
0.9679 (56 to 87)0.0080.45 (0.25 to 0.82)11 89224249NAOR25OHDType 2 diabetes
(prevalent)
Neonatal/infant/child related outcomes
NANA0.410.19 (−0.26 to 0.65
)
840NA2cmWMD25OHDBirth length
NANA5.5×10−6130.9 (75.1 to
186.7)
5541NA4gramsWMD25OHDBirth weight
NANA0.760.05 (−0.24 to 0.34)840NA2cmWMD25OHDHead circumference
0.818 (0 to 64)1.8×10−80.54 (0.44 to 0.67)6851NA6NAOR25OHDSmall for gestational
age
Pregnancy related outcomes
0.580 (0 to 53)0.00090.67 (0.53 to 0.85)411268710NAOR25OHDGestational diabetes
0.960 (0 to 58)0.0020.56 (0.39 to 0.8)32303939NAOR25OHDPre-eclampsia
Skeletal outcomes
0.7877 (66 to 83)1.3×10−130.31 (0.23 to 0.42)2956157228NASMD (to OR)25OHDFractures
NANANA−0.26 (−0.33 to
−0.23)
220111168nmol/Llog ratio of
geometric
mean
25OHDHip fracture (hospital
based controls)
NANANA−0.51 (−0.64 to
−0.38)
16558189nmol/Llog ratio of
geometric
mean
25OHDHip fracture
(population based
controls)
Other outcomes
0.0931 (0 to 66)4.6×10−60.86 (0.81 to 0.92)6853211010NARR25OHDAll cause mortality
(in CKD patients)
0.2982 (72 to 87)2.9×10−130.72 (0.66 to 0.78)77 15515 44718NAHR25OHDAll cause mortality
CKD=chronic kidney disease; HR=hazard ratio; MA=meta-analysis; NA=not applicable; OR=odds ratio; RR=relative risk; SMD=standardised mean difference;
WMD=weighted mean difference.
P values were estimated using formulas presented in Altman and Bland 2011.140
*Effect estimate and 95% CI estimated based on random effects model. Reported effect estimates and 95% CI are presented for hip fracture (population based
controls), hip fracture (hospital based controls), birth length, head circumference, and birth weight.
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Table 3| General characteristics of non-overlapping meta-analyses of randomised controlled trials of vitamin D supplementation for
cardiovascular, metabolic, neonatal/infant/child related, pregnancy related, and other outcomes
P value
Reported summary effect
(95% CI)
No of
studies in
each MAMA modelUnits
Type of metric
(summary
effect)PopulationOutcome
Cardiovascular outcomes
0.320.95 (0.86 to 1.05)2FixedNARRGeneralCardiovascular disease
0.98−0.03 (−1.98 to 1.92)3No infomm HgWMDNormotensive or
hypertensive
Diastolic blood pressure
0.16−2.39 (−5.7 to 0.9)3No infomm HgWMDNormotensive or
hypertensive
Systolic blood pressure
Metabolic disorders
0.940.01 (−0.21 to 0.23)No infoNo infonmol/LWMDDiabetes patients with
normal glucose
tolerance
Fasting glucose
0.33−0.3 (−0.9 to 0.3)No infoNo infonmol/LWMDDiabetes patients with
abnormal glucose
tolerance
Fasting glucose
0.76−0.14 (−0.99 to 0.71)8Fixedmg/dLWMDGeneralHigh density lipoprotein
0.240.16 (−0.11 to 0.42)5No infoNASMDDiabetesInsulin resistance
0.321.52 (−1.42 to 4.46)11Fixedmg/dLWMDGeneralTotal cholesterol
0.023.23 (0.55 to 5.9)7Fixedmg/dLWMDGeneralLow density lipoprotein
0.53−1.92 (−7.72 to 3.88)8Fixedmg/dLWMDGeneralTriglycerides
Neonatal/infant/child related outcomes
0.170.97 (−0.41 to 2.34)2RandomcmWMDPregnant womenBirth length
0.0010.4 (0.23 to 0.71)3FixedNARRPregnant womenLow birth weight
3.7×10−90.53 (0.43 to 0.65)38RandomNARRChildrenDental caries
0.020.43 (0.06 to 0.79)2RandomcmWMDPregnant womenHead circumference at birth
0.120.67 (0.40 to 1.11)2FixedNARRPregnant womenSmall for gestational age
Pregnancy related outcomes
8.7×10−547.08 (23.76 to 70.39)4Randomnmol/LWMDPregnant womenMaternal vitamin D
concentrations at term
0.320.17 (-0.16 to 0.51)2FixedWeeksWMDPregnant womenMean gestational age at
delivery
0.520.77 (0.35 to 1.66)2FixedNARRPregnant womenPreterm delivery
Other outcomes
0.06−21.81 (−40.39 to 3.22)2FixedU/LWMDCKD NRDAlkaline phosphatase
0.02−27.35 (−50.69 to −4.01)3FixedU/LWMDCKD RDAlkaline phosphatase
0.54−1.68 (−6.92 to 3.56)4FixedmL/minWMDCKD NRDCreatinine clearance
0.090.91 (0.82 to 1.02)9RandomNARRGeneral (vitamin D3)Mortality
0.261.04 (0.97 to 1.11)8RandomNARRGeneral (vitamin D2)Mortality
0.631.40 (0.38 to 5.15)4FixedNARRCKD NRDMortality
0.691.34 (0.34 to 5.24)5FixedNARRCKD RDMortality
0.008−49.34 (−85.70 to −12.97)4Fixedpmol/LWMDCKD NRDParathyroid hormone
0.0002−196.05 (−298.43 to −93.66)6Fixedpmol/LWMDCKD RDParathyroid hormone
0.900.82 (0.05 to 12.47)2FixedNARRCKD RDParathyroidectomy
0.023.04 (1.17 to 7.90)7FixedNARRCKD NRDRisk of hypercalcaemia
0.073.80 (0.90 to 16.12)5FixedNARRCKD RDRisk of hypercalcaemia
0.471.58 (0.47 to 5.30)2FixedNARRCKD NRDRisk of hyperphosphataemia
0.071.57 (0.97 to 2.54)2FixedNARRCKD RDRisk of hyperphosphataemia
0.480.76 (0.36 to 1.62)4FixedNARRCKD NRDRisk of requiring dialysis
0.330.41 (0.07 to 2.38)3FixedNARRCKD RDSubperiosteal erosions
0.861.09 (0.45 to 2.67)2FixedNARRCKD RDVascular calcification
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Table 3 (continued)
P value
Reported summary effect
(95% CI)
No of
studies in
each MAMA modelUnits
Type of metric
(summary
effect)PopulationOutcome
CKDNRD=chronic kidney disease not requiring dialysis; CKD RD=chronic kidney disease requiring dialysis; RR=relative risk; SMD=standardised mean difference;
WMD=weighted mean difference.
P values were estimated using formulas presented in Altman and Bland 2011.140
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Table 4| General characteristics of non-overlappingmeta-analyses of randomised controlled trials of vitamin D supplementation for skeletal
outcomes
P value
Reported summary
effect (95% CI)
No of
studies in
each MAMA modelUnits
Type of metric
(summary
effect)PopulationSkeletal outcome
0.220.1 (−0.06 to 0.26)5Fixed% changeSMDHealthy childrenBone mineral density
0.16−0.9 (−2.10 to 0.40)3Random% changeWMDCommunity dwelling adultsBone mineral density
0.0041.10 (0.40 to 1.90)8Random% changeWMDCommunity dwelling adultsBone mineral density in
femoral neck
0.19−0.70 (1.70 to 0.40)2Random% changeWMDCommunity dwelling adultsBone mineral density in
forearm
0.860.04 (−0.36 to 0.45)3Random% changeSMDHealthy childrenBone mineral density in
forearm
0.630.06 (−0.18 to 0.29)4Random% changeSMDHealthy childrenBone mineral density in hip
0.110.70 (−0.10 to 1.60)6Random% changeWMDCommunity dwelling adultsBone mineral density in hip
0.070.15 (−0.01 to 0.31)5Fixed% changeSMDHealthy childrenBone mineral density in
lumbar spine
0.780.10 (−0.60 to 0.70)7Random% changeWMDCommunity dwelling adultsBone mineral density in
lumbar spine
0.280.29 (0.03 to 2.63)4FixedNARRCKD RDBone pain
0.680.97 (0.84 to 1.11)10RandomNAOROlder adultsFalls
0.280.55 (0.19 to 1.64)2RandomNARaROlder people in care
facilities or hospitals
Falls: rate of falls
0.011.14 (1.03 to 1.27)2RandomNARaROlder people in communityFalls: rate of falls
0.821.01 (0.93 to 1.09)10FixedNARRMen aged >65 years and
postmenopausal women
Fractures
1.001.00 (0.06 to 15.41)4FixedNARRCKD RDFractures
0.061.15 (0.99 to 1.33)9FixedNARRMen aged >65 years and
postmenopausal women
Fractures: hip
0.040.79 (0.63 to 0.99)5No infoNARRPeople aged >65 yearsFractures: non-vertebral
0.490.69 (0.21 to 1.66)2RandomNAOROlder womenFractures: non-vertebral,
non-hip
0.800.90 (0.42 to 1.92)5RandomNARRMen aged >65 years and
postmenopausal women
Fractures: vertebral or
deformity
0.04−0.20 (−0.39 to −0.01)3FixedNASMDOlder adultsPerformance measures:
balance sway
0.540.05 (−0.11 to 0.20)3FixedNASMDOlder adultsPerformance measures:
lower extremity strength
0.02−0.19 (−0.35 to −0.02)3FixedNASMDOlder adultsPerformance measures:
muscle strength
CKD RD=chronic kidney disease requiring dialysis; OR=odds ratio; RaR=rate ratio; RR=relative risk; SMD=standardised mean difference; WMD=weighted mean
difference.
P values were estimated using formulas presented in Altman and Bland 2011.140
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Table 5| Overlap between meta-analyses of observational studies and vitamin D supplementation randomised controlled trials
CI excluded null
Concordant
direction
Randomised controlled trialsObservational
Disease outcome
Observational
onlyBothEffect size (95% CI)MetricEffect size (95% CI)Metric
YesNoYes0.95 (0.86 to 1.05)OR0.66 (0.57 to 0.77)ORCardiovascular disease102 130
YesNoYes−2.39 (−5.7 to 1.92)WMD0.70 (0.58 to 0.86)ORHypertension/blood
pressure104 127
NoYesYes0.4 (0.23 to 0.71)OR130.9 (75.1 to 186.7)WMDBirth weight/ risk of low birth
weight36 61
NoNoYes0.97 (−0.41 to 2.34)WMD0.19 (−0.26 to0.65 )WMDBirth length36 112
NoNoYes0.43 (0.06 to 0.79)WMD0.05 (−0.24 to 0.34)WMDHead circumference36 112
YesNoYes0.67 (0.4 to 1.11)OR0.54 (0.44 to 0.67)ORSmall for gestational age36 61
YesNoNo1.4 (0.38 to 5.15)OR0.86 (0.81 to 0.92)ORMortality in CKD patients84 120
YesNoYes0.91 (0.82 to 1.02)OR0.72 (0.66 to 0.78)ORAll cause mortality66 110
YesNoNo1.01 (0.93 to 1.09)OR0.31 (0.23 to 0.42)ORFractures in older
populations91 107
YesNoNo1.15 (0.99 to 1.33)OR−0.26 (−0.33 to −0.23)Log ratio of
geometric mean
Hip fracture37 107
CI=confidence interval; CKD=chronic kidney disease; OR=odds ratio; WMD=weighted mean difference.
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Table 6| Evidence of relation between high vitamin D concentrations or vitamin D supplementation and clinical outcomes
Heath risksHealth benefitsEvidence category*
NoneNoneConvincing
NoneDecreases risk of dental caries in childrenProbable
Increases levels of birth weight and maternal vitamin D concentrations at term
Decreases levels of parathyroid hormone concentrations in CKD RD
Increases rate of falls
(community) and risk
of hypercalcaemia in
CKD NRD
Decreases risk of colorectal cancer, non-vertebral fractures, CVD, CVD prevalence, hypertension, ischaemic stroke,
stroke, cognition, depression (cohort studies), body mass index, metabolic syndrome prevalence, type 2 diabetes,
small for gestational age birth, gestational diabetes mellitus
Suggestive
Decreases levels of balance sway, alkaline phosphatase concentrations in CKD RD, parathyroid hormone
concentrations in CKD NRD
Increases levels of head circumference at birth, LDL, bone mineral density in femoral neck, muscle strength
Increases risk of
pancreatic cancer,
hyperphosphataemia
in CKD, vascular
calcification in CKD
RD, hypercalcaemia in
CKD RD
Decreases risk of ankylosing spondylitis, Crohn’s disease, multiple sclerosis, osteoarthritis, rheumatoid arthritis,
rheumatoid arthritis activity, scleroderma, systemic lupus erythematosus, thyroid autoimmunity, type 1 diabetes,
type 1 diabetes in childhood (maternal vitamin D status), vitiligo, breast cancer, breast cancer prognosis, colon
cancer, colorectal adenoma, colorectal adenoma recurrence, colorectal cancer prognosis, lung cancer, melanoma
prognosis, non-Hodgkin’s lymphoma, non-small cell lung cancer prognosis, oesophageal cancer, ovarian cancer,
prostate cancer prognosis, rectal cancer, renal cancer, stomach cancer, CVD in ethnic minorities, CVD mortality,
hypertension in children, ischaemic heart disease, myocardial infarction, Alzheimer’s disease, depression (case-control
No conclusion
studies), active tuberculosis, acute respiratory infection, infectious disease mortality, metabolic syndrome in ethnic
minorities, obesity in ethnic minorities, type 2 diabetes in ethnic minorities, type 2 diabetes prevalence, allergic
rhinitis and atopic dermatitis/eczema (maternal vitamin D status), cerebral function and diseases (maternal vitamin
D status), childhood infections (maternal vitamin D status), wheezing and asthma in childhood (maternal vitamin D
status), bacterial vaginosis in pregnant women, fertility, postpartum depression, pre-eclampsia in pregnant women,
pregnancy associated breast cancer, bone health in pregnant and lactating women, bone pain in CKD RD, falls,
rate of falls (care facilities), fractures in older people, fractures in CKD RD, hip fractures, non-vertebral non-hip
fractures, vertebral fractures or deformity, performance measures in older people, rickets in children, all cause
mortality, mortality in CKD, risk of requiring dialysis in CKD NRD, parathyroidectomy in CKD RD, subperiosteal
erosions in CKD RD, mammographic breast density
Decreases levels of HDL in children, LDL in children, triglycerides in children, insulin/glucose metabolism in children,
triglycerides, insulin resistance of diabetes patients, bone mineral density, bone mineral density in forearm, alkaline
phosphatase concentrations in CKD NRD, creatinine clearance in CKD
Increases levels of total cholesterol concentrations, neonatal and infant growth, length of gestation, bone mineral
content in infants, bone mineral density in hip, bone mineral density in lumbar spine (children)
NoneDecreases risk of aggressive prostate cancer, premenopausal breast cancer, postmenopausal breast cancer, cancer
mortality, kidney cancer, prostate cancer, caesarean section
Substantial effect
unlikely
Decreases levels of fasting glucose in diabetes patients, HDL, adiposity in children (maternal vitamin D status)
Increases levels of birth length (maternal vitamin D status), bone mineral density in children, bone mineral density
in forearm in children, bone mineral density in hip in children, bone mineral density in lumbar spine, lower extremity
strength
CKD=chronic kidney disease; CVD=cardiovascular disease; HDL=high density lipoprotein; LDL=low density lipoprotein; NRD=not requiring dialysis; RD=requiring
dialysis.
*See box.
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Figures
Fig 1 Flow chart of eligible studies
Fig 2 Map of 137 vitamin D related outcomes: percentage of outcomes per outcome category for all study designs
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Fig 3 Forest plot of all meta-analyses of observational studies stratified by measured biomarker with relative risk as type
of metric
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;348:g2035 doi: 10.1136/bmj.g2035 (Published 1 April 2014) Page 18 of 19
RESEARCH
Fig 4 Forest plot of all meta-analyses of randomised controlled trials with relative risk as type of metric by compound
administered. CKD=chronic kidney disease patients; NRD=not requiring dialysis; RD=requiring dialysis; UV=ultraviolet
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